Zolimomab aritox

Drug Profile

Zolimomab aritox

Alternative Names: Anti-CD5 monoclonal antibody-ricin-chain-A conjugate; Anti-CD5 ricin A chain immunotoxin; CD5 Plus; CD5+; Muromonab; Orthozyme CD5 Plus; Xomazyme CD5 Plus; XZ-CD5

Latest Information Update: 28 Jun 1999

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cancer Research UK
  • Developer Ortho-McNeil; XOMA
  • Class Immunotoxins; Monoclonal antibodies
  • Mechanism of Action CD5 antigen inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetes mellitus; Graft-versus-host disease; Renal transplant rejection; Rheumatoid arthritis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 28 Jun 1999 Discontinued-II for Rheumatoid arthritis in USA (Unknown route)
  • 18 Aug 1998 No-Development-Reported for Rheumatoid arthritis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top